Whole Exome Sequencing Market Scope And Analysis

  • Report Code : TIPRE00005519
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Whole Exome Sequencing Market Analysis and Scope (2024 to 2031)

Buy Now


Whole Exome Sequencing Market Report Scope

Report Attribute Details
Market size in 2023 US$ 414.5 Million
Market Size by 2031 US$ 1,457.8 Million
Global CAGR (2023 - 2031) 17.02%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Products & Services
  • Systems
  • Kits
  • Services
By Technology
  • Sequencing Synthesis
  • Ion Semiconductor Sequencing
  • Other Technologies
By Application
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Other Application
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Thermo Fisher Scientific Inc
  • Illumina Inc
  • Centogene AG
  • F Hoffmann La Roche AG
  • Psomagen Inc previously Macrogen Corp
  • Pacific Biosciences of California Inc
  • GENEWIZ Inc
  • Bio Rad Laboratories Inc
  • Eurofins Scientific
  • Stratos Genomics
  • Whole Exome Sequencing Market News and Recent Developments

    The whole exome sequencing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the whole exome sequencing market are listed below:

    • Illumina Inc. announced that its first product, based on its novel Illumina Complete Long Read technology, is available for order. The high-performance, long-read, human whole-genome sequencing assay – Illumina Complete Long Read Prep, Human – is compatible with the company’s NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. It offers users access to both long- and short-read data on the same Illumina instrument. (Source: Illumina Inc., Press Release, March 2023)
    • Helix, the leading population genomics company, has received de novo authorization from the US Food & Drug Administration (FDA) for the Helix Laboratory Platform, a whole exome sequencing platform with coverage of approximately 20,000 genes. Additionally, Helix also received 510(k) clearance for the Helix Genetic Health Risk App for late-onset Alzheimer's Disease for over-the-counter use on the Helix Laboratory Platform. (Source: Helix, Press Release, January 2021)

    Whole Exome Sequencing Market Report Coverage and Deliverables

    The “Whole Exome Sequencing Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Whole exome sequencing market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Whole exome sequencing market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Whole exome sequencing market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Whole exome sequencing market
    • Detailed company profiles